Eysuvis Now Available For Dry Eye Disease
Eysuvis (loteprednol etabonate ophthalmic suspension) is now available for the short-term treatment of the signs and symptoms of dry eye disease.
Ophthalmic Disorders
NDA Submitted for MydCombi, a Novel Mydriatic Agent
The NDA submission is supported by data from the phase 3 MIST-1 and MIST-2 studies.
New Drugs Approved in 2020
Visit our New Drug Products page to stay up-to-date on the latest drug approvals.
Tepezza Supply Shortage Expected Soon
As both the vaccine and Tepezza are being manufactured at Catalent, the government has prioritized the manufacturing of the vaccine thereby resulting in cancellation of previously contracted Tepezza orders.
Dry Eye Treatments
Over-the-counter (OTC) and prescription agents for the management of dry eye.
MPR Weekly Dose Podcast Episode 56
This week we cover a study that identified factors associated with strong antibody responses to COVID; How convalescent plasmas benefits may be limited; A nasal spray to treat diabetic gastroparesis; Recommendations for colorectal cancer screening; And a new treatment approved for dry eye disease. And of course, movie trivia!
Eysuvis Approved for Dry Eye Disease
Results from 4 clinical trials showed that treatment with Eysuvis was associated with significant improvements in both the signs and symptoms of dry eye disease.
Cyclosporine Eyedrops Under Review for Vernal Keratoconjunctivitis
Vernal keratoconjunctivitis is a rare allergic eye disease that affects the pediatric population and results in severe inflammation of the surface of the eye.
Preservative-Free Alaway Gets FDA Approval for OTC Use
The new formulation does not contain benzalkonium chloride.
Cystadrops Now Available for Patients With Cystinosis
The Food and Drug Administration approved Cystadrops in August 2020.
